Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis

Lucaciu, Laura; Constantine‐Cooke, Nathan; Plevris, Nikolas; Siakavellas, Spyros I.; Derikx, Lauranne; Jones, G. R.

doi:10.1177/17562848211064004

Cited by 22 publications

(17 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Methodsmentioning

confidence: 99%

“…As part of the comprehensive search strategy, we searched meta-analysis studies and scientometric and bibliometric analyses. Based on the search strategies employed in these studies (Connelly et al, 2016;Schöffel et al, 2016;Nguyen et al, 2018;Lucaciu et al, 2021;Schöffel et al, 2021), we used advanced search to identify publications relevant to UC with the following query: TOPIC: [(ulcerativ* AND colitis) OR (ulcerativ* AND enteritis) OR (colitis ulcerosa) OR (enteritis ulcerosa) OR (idiopathic proctocolitis) OR (colitis gravis) OR (colitis chronica purulenta) OR (colitis polyposa) OR (gastroenteritis ulcerosa) OR (backwash ileitis)] AND Language: (English). Timespan: 2011Timespan: -2012 This study focused, for the purpose of this analysis, on articles (document types) that included original research articles, case reports, and case series out of the different types of documents indexed in the database (article, proceedings paper, review, meeting abstract, correction, letter, editorial material, note, book chapter, news item, and correction addition).…”

Section: Source Of the Data And Search Strategymentioning

confidence: 99%

“…In the early years from 2011 to 2013, UC research began to focus on (Actis et al, 2019) cystic fibrosis, asthma, breast cancer, and osteoporosis (Kaplan, 2015); primary sclerosing cholangitis, rheumatoid arthritis, systemic lupus erythematosus, and ankylosing spondylitis (Wilks, 1859); celiac disease, pouchitis, and familial adenomatous polyposis (Viola et al, 2021); abnormal motility, colonic permeability, and enteric nervous system (Nguyen et al, 2018); adipose tissue (Lucaciu et al, 2021); epidemiology, gene polymorphism, susceptibility loci, drug delivery, and activity index (Connelly et al, 2016); dextran sulfate sodium (DSS) and acetic acid (Schöffel et al, 2021); guinea pig (Schöffel et al, 2016); N-acetylcysteine, fish oil, and vitamin D (Chen, 2006); 5-aminosalicylic acid (5-ASA), sulfasalazine, olsalazine, and chitosan (Van Eck and Waltman, 2010); cyclosporin, 6-mercaptopurine, methotrexate, and azathioprine (Aksnes, 2003); certolizumab pegol, infliximab, etanercept, adalimumab, and tacrolimus (Bardeesi et al, 2021); Adacolumn, leukocytapheresis, and apheresis (Freeman, 1977); probiotics, antibiotic therapy, curcumin, traditional Chinese medicine, and electroacupuncture (Cobo et al, 2011); colectomy, ileostomy, and ileal pouch-anal anastomosis; (Kessler, 1963); liver transplantation (Marshakova, 1973); confocal laser endomicroscopy and PillCam colon capsule endoscopy (Small, 1973); C-reactive protein, lactoferrin, and fecal calprotectin (Sandborn et al, 2012a); E-cadherin (Sandborn et al, 2017); Epstein-Barr virus and cytomegalovirus infection (Feagan et al, 2013); Helicobacter pylori, gut microbiota, Escherichia coli, and Clostridium difficile infection (Kleinberg, 2003); short-chain fatty acids, butyrate, and bile acid (Cohen et al, 2010); innate immunity (Ng et al, 2017); regulatory T (T reg ) cell, T helper 17 (Th17) cell, natural killer T cell, and mast cell (Burisch et al, 2020); enterochromaffin cell (Livas et al, 2021); antineutrophil cytoplasmic antibody and anti-Saccharomyces cerevisiae antibody (Glänzel and Thijs, 2004); angiogenesis...…”

Section: Keyword Analysismentioning

confidence: 99%

See 2 more Smart Citations

Research trends in ulcerative colitis: A bibliometric and visualized study from 2011 to 2021

Zhang

Tian

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Ulcerative colitis (UC) is an idiopathic inflammatory bowel disease with repeated relapses and remissions. Despite decades of effort, numerous aspects, including the initiating event and pathogenesis of UC, still remain ambiguous, which requires ongoing investigation. Given the mass of publications on UC, there are multidimensional challenges to evaluating the scientific impact of relevant work and identifying the current foci of the multifaceted disease. Accordingly, herein, we aim to assess the global growth of UC research production, analyze patterns of research areas, and evaluate trends in this area.Methods: The Web of Science Core Collection of Clarivate Analytics was searched for articles related to UC published from 2011 to 2021. Microsoft Office Excel 2019 was used to visualize the number of publications over time. Knowledge maps were generated using CiteSpace and VOSviewer to analyze collaborations among countries, institutions, and authors and to present the journey of UC research as well as to reveal the current foci of UC research.Results: A total of 5,088 publications were evaluated in the present study. China had the most publications (1,099, 22.5%). Univ Calif San Diego was the most productive institution (126, 2.48%). William J Sandborn published the greatest number of articles (100, 1.97%). Toshifumi Hibi was the most influential author in the field with a betweenness centrality of 0.53. Inflammatory bowel diseases was identified as the most prolific journal (379, 7.45%). Gastroenterology was the most co-cited journal (3,730, 4.02%). “Vedolizumab,” “tofacitinib,” “Faecalibacterium prausnitzii,” “fecal microbiota transplantation (FMT),” “toll-like receptor 4,” and “nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome” were considered the hot topics.Conclusion: In UC research, manuscripts that had high impacts on the scientific community provided an evidence base. UC therapy has entered the era of personalized and precision therapy. As research on FMT, anti-integrin antibodies, Janus kinase inhibitors, and anti-tumor necrosis factor drugs continues to grow, their use in the clinical setting may also expand.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Source Of the Data And Search Strategymentioning

confidence: 99%

Section: Keyword Analysismentioning

confidence: 99%

See 1 more Smart Citation

Research trends in ulcerative colitis: A bibliometric and visualized study from 2011 to 2021

Zhang

Tian

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The first reported serious adverse event rate in the analysed studies of 4.4%; however, the number of malignant events was not further described 50. The second identified one case of malignancy (metastatic breast cancer) among the reported adverse events over a median follow-up of 31 weeks 51. This case was attributed to high prior immunosupressive load 52.…”

Section: Introductionmentioning

confidence: 95%

“…Of note, the real-world IBD tofacitinib studies and trial data encapsulated a younger population (mean age approx. 40) 48 51…”

Section: Introductionmentioning

confidence: 99%

Managing IBD in patients with previous cancers

Minnis-Lyons

Aiken

Chow

et al. 2022

Frontline Gastroenterol

View full text Add to dashboard Cite

A frequent dilemma faced in the inflammatory bowel disease (IBD) clinic is how to best treat a patient with a previous cancer diagnosis. The changing demographics of our patient population will make this quandary more common. Previous guidance has emphasised the importance of lengthy postcancer drug holidays and cautious use of IBD therapies. However, accumulating evidence suggests this approach may be unnecessarily conservative. This review considers recent evidence on the safety of IBD drugs, cancer and recurrent cancer risk in patients with IBD and provides a framework for shared decision making involving patient, gastroenterologist and oncologist.

show abstract

Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database

Chiorean,

Ha,

Hur

et al. 2023

Dig Dis Sci

View full text Add to dashboard Cite

Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Aims To evaluate real-world data in US patients with UC receiving tofacitinib. Methods Characteristics and outcomes of patients with UC initiating tofacitinib between 2018 and 2019 were assessed using data from the IBM® MarketScan® claims database. The index date was the first tofacitinib claim; pre- and post-index periods were 12 months. Outcomes included tofacitinib adherence/persistence, oral corticosteroid (OCS) use, and healthcare resource utilization (HCRU) and costs. Results Of 276 patients with UC who initiated tofacitinib, 68 (24.6%) were bio-naïve, and 208 (75.4%) bio-experienced. At month 12, overall median tofacitinib adherence (proportion of days covered) was 0.82 (mean 0.68); 43.8% of patients discontinued tofacitinib (90-day gap). Of patients receiving OCS during the post-index 16-week tapering period, 40.4% discontinued OCS up to 12 months post-index. OCS use decreased in patients continuing tofacitinib versus those discontinuing tofacitinib (29.7% vs 59.5%, respectively). Reductions in all-cause and UC-related outpatient visits were observed for bio-naïve (− 1.34 and − 0.88, respectively) and bio-experienced (− 4.72 and − 5.16, respectively) patients, post-index. Decreased UC-related costs per year were observed for bio-experienced patients (difference in post-index vs pre-index, − US$12,448; driven by changes in pharmacy costs), but not for bio-naïve patients (US$47,152). Conclusions In this real-world analysis in a mostly bio-experienced population, the majority of US patients with UC initiating tofacitinib remained on therapy at 12 months, and OCS use was reduced with tofacitinib treatment. HCRU (all patients) and UC-related costs were reduced in bio-experienced patients. Graphical Abstract The majority of patients with ulcerative colitis starting tofacitinib in this real-world study continued therapy at 12 months; there was a reduction in the use of steroids, and a decrease in healthcare resournce utilization and costs. Supplementary Information The online version contains supplementary material available at 10.1007/s10620-023-08063-4.

show abstract

Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis

Cited by 22 publications

References 68 publications

Research trends in ulcerative colitis: A bibliometric and visualized study from 2011 to 2021

Research trends in ulcerative colitis: A bibliometric and visualized study from 2011 to 2021

Managing IBD in patients with previous cancers

Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database

Contact Info

Product

Resources

About